牛牛AI助理已提取核心訊息
Alon Ben-Noon, an Israeli citizen, has filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, indicating a significant ownership stake in NeuroSense Therapeutics Ltd. As of December 31, 2023, Ben-Noon beneficially owns 3,072,600 ordinary shares of NeuroSense Therapeutics, which represents 19.98% of the company's class of securities. This stake includes 36,000 restricted share units that vested during the year. The filing, dated February 13, 2024, confirms that the information provided is true and complete to the best of Ben-Noon's knowledge after reasonable inquiry.
Alon Ben-Noon, an Israeli citizen, has filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, indicating a significant ownership stake in NeuroSense Therapeutics Ltd. As of December 31, 2023, Ben-Noon beneficially owns 3,072,600 ordinary shares of NeuroSense Therapeutics, which represents 19.98% of the company's class of securities. This stake includes 36,000 restricted share units that vested during the year. The filing, dated February 13, 2024, confirms that the information provided is true and complete to the best of Ben-Noon's knowledge after reasonable inquiry.
以色列公民阿隆·本·努恩已向美國證券交易委員會提交了附表13G/A的修正案，表示擁有NeuroSense Therapeutics Ltd的大量所有權。截至2023年12月31日，Ben-Noon實益擁有NeuroSense Therapeutics的3,072,600股普通股，佔該公司證券類別的19.98％。該股份包括年內歸屬的36,000股限制性股票單位。這份日期爲2024年2月13日的文件證實，經過合理的調查，據本·努恩所知，所提供的信息是真實和完整的。
以色列公民阿隆·本·努恩已向美國證券交易委員會提交了附表13G/A的修正案，表示擁有NeuroSense Therapeutics Ltd的大量所有權。截至2023年12月31日，Ben-Noon實益擁有NeuroSense Therapeutics的3,072,600股普通股，佔該公司證券類別的19.98％。該股份包括年內歸屬的36,000股限制性股票單位。這份日期爲2024年2月13日的文件證實，經過合理的調查，據本·努恩所知，所提供的信息是真實和完整的。
有用
沒用
